Replimune Group (REPL) news
Recent news
Replimune: Tudriqev available in US for advanced melanoma
Replimune, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced…
AInvest Wire · Oct 1, 2026Replimune Group - Approves amendment to increase authorized common shares to 300,000,000 - SEC filing
AInvest Wire · Sep 16, 2026Replimune Group, Inc. files for mixed shelf; size not disclosed - SEC filing
Replimune Group, Inc. (Nasdaq: REPL) has filed a new shelf registration statement with the U.S. Securities and Exchange Commission (SEC), which allows the company to offer and sell securities from time to time in the future without disclosing the specific size of the offering in the filing. Shelf…
AInvest Wire · Aug 14, 2026Replimune prices offer of 9.7M shares at $12.06/shr
Replimune Group Inc. has announced the pricing of its underwritten public offering of 9.7 million shares at $12.06 per share [1]. The offering is part of the company’s ongoing efforts to raise capital to support its research and development initiatives. The shares are being offered by the company…
AInvest Wire · Aug 10, 2026Replimune announces pricing of $150M underwritten offering
AInvest Wire · Aug 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.